gp100 melanoma antigen DNA vaccine: VICL began a Phase I/II trial

By WIR Staff | Jul 13, 1998 | 7:00 AM GMT

Vical Inc. (VICL), San Diego, Calif.
Product: gp100

Read the full 87 word article

How to gain access

Continue reading with a
two-week free trial.